Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
about
Oncolytic viruses as therapeutic cancer vaccinesSafety, activity, and immune correlates of anti-PD-1 antibody in cancerProteomic-Based Approaches for the Study of Cytokines in Lung CancerNon-small cell lung cancer: current treatment and future advancesImmune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?Immunotherapy for head and neck cancer: latest developments and clinical potentialCheckpoint Inhibitors and Their Application in Breast CancerAdvances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerMolecular therapeutics in pancreas cancerRegulation of Natural Killer Cell Function by STAT3Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsImmune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumPredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisNovel technologies and emerging biomarkers for personalized cancer immunotherapyTargeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaClinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-AnalysisHuman IgG4: a structural perspectiveThe potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapyThe Evolution of Therapies in Non-Small Cell Lung CancerEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityThe progress of immunotherapy for glioblastomaRole of the PD-1 pathway in the immune responseOvercoming T cell exhaustion in infection and cancerInterleukin-27: balancing protective and pathological immunitySystemic and targeted therapies for early-stage lung cancerMechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissuesPeripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfallsUpdate on the challenges and recent advances in cancer immunotherapyHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyTargeted therapies in development for non-small cell lung cancerIndividualising treatment choices in a crowded treatment algorithmAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaStructure and Interactions of the Human Programmed Cell Death 1 ReceptorPD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined SubgroupsPD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.PD-1 and its ligands are important immune checkpoints in cancerImmunotherapy in urothelial carcinoma: fade or future standard?Immune checkpoint therapy for pancreatic cancerAdvances in Cancer Immunotherapy in Solid TumorsCancer stem cells in basic science and in translational oncology: can we translate into clinical application?
P2860
Q21245758-58C5B04C-C3B6-425F-B93B-25711905CC8FQ24633070-9A05D784-1BDF-41E2-BFF4-EA1995C4B233Q26738539-04668E90-D7C3-4850-AAE8-52AA414DBEFDQ26740333-7C12328B-F9F7-4AD6-8A41-52E2BFCE2688Q26740601-2457B1F0-B51C-42F2-B4CE-C9C816AE036BQ26745428-3630E982-CFE4-4753-864E-EE5CE4E34DF1Q26745442-E9D25403-839A-444A-91FF-1DF59A29CD9FQ26749451-B0EEAA18-C7B0-476F-9AEB-E157D9980E62Q26751709-8F32CDB0-D8B7-47E9-9BE9-89C253244767Q26752551-D839EE0B-0729-4B69-A693-A1B7AF66736DQ26753082-34164F0E-E4FB-42DB-9DAE-480597F8EB79Q26765459-53352815-29B7-46D6-8D12-8E0D7789D0D8Q26769728-52E3F058-6847-4E05-95E1-6D1820374EC6Q26770780-2DBD6CC1-0ACD-4AAA-B3DE-A132458A6DDEQ26775769-42383144-3241-4EB5-A28A-74B2D58CEC6AQ26778025-D29B8A4B-947D-4E95-B101-7471041A03AAQ26779758-83396E34-B7C0-4EEE-A7E6-C5796B8BEA9AQ26783291-4873CFCF-1467-44E8-8649-3907851BEBF5Q26786932-74395275-4CC1-4939-9759-7DB222E86111Q26796313-7F81F64B-F30B-4D11-A5AF-2689EA81AAEEQ26797282-5DB9861F-3A42-4A8F-8435-39CE92A24711Q26828748-69769D36-524D-4B7E-AF40-61EA15249FC5Q26829885-E692B108-CE7D-4D9F-92C8-BBE3926D7B2CQ26830400-223CFAD3-FDB5-4F84-8937-4FA792282BEAQ26865490-05213897-A6E7-4F79-967F-AA2F9E6B7423Q27003907-995CEA6F-996F-41A2-9993-DE401E6B0983Q27004241-AF351F67-C5EC-41EE-A2D9-E3F06B09D2A0Q27014693-487F8B9D-4F3E-4A0D-B4F5-DDFCA0AAAD7EQ27021570-5279DCFC-AF2C-41E5-9AA3-97509D2BF22DQ27022852-D23A128F-698C-467F-8115-443AF3BE4889Q27023669-BADB00C9-065F-4A7F-9AD9-C24E0141AB49Q27024830-6E06EBD1-04B9-47ED-8536-188AE7BCE09AQ27676419-F9AFFC6B-23A3-4E0A-B600-B08B0A58FEF1Q27853205-65137465-B94D-4A97-AB44-BF309CCE1832Q27853353-5D9B18E3-AB66-4723-BF30-63737D69411DQ28069485-0413A864-6A1F-45F1-8DBB-71DB05AA4032Q28078284-70CF7630-DD68-4EA8-9BC1-3181FDB34C21Q28078390-B3F4EA20-0950-4643-A250-7DA61F618954Q28080113-3D47AC74-3A53-4EFD-AABD-19EF30CF8736Q28081844-B8A7C480-4149-4BB4-9F22-BC4A62C21F32
P2860
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
@ast
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
@en
type
label
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
@ast
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
@en
prefLabel
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
@ast
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
@en
P2093
P2860
P1476
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
@en
P2093
Charles G Drake
Drew M Pardoll
Suzanne L Topalian
P2860
P304
P356
10.1016/J.COI.2011.12.009
P577
2012-01-09T00:00:00Z